Embolotherapy Market Revenue to Reach US$ 5,758.28 Million by 2028

The embolotherapy market is expected to grow from US$ 3,341.49 million in 2021 to US$ 5,758.28 million by 2028; it is estimated to grow at a CAGR of 8.1% from 2022 to 2028.

According to our new research study on "Embolotherapy Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Product, Disease Indication, Procedure, and End User," the market is expected to grow from US$ 3,341.49 million in 2021 to US$ 5,758.28 million by 2028. It is estimated to grow at a CAGR of 8.1% during 2022-2028.

Get sample PDF copy @ https://www.theinsightpartners.com/sample/TIPRE00006432/?utm_source=OpenPR&utm_medium=10381

Factors driving the growth of the embolotherapy market are rising incidence of cancer cases, rising patient preference for minimally invasive procedures, and increasing incidence of hypertension, obesity, smoking, and alcoholism. The availability of alternative therapies and the high cost of embolization agents hinder the overall market growth.

Key Players : Abbott Laboratories, Boston Scientific Corporation, Cook Medical LLC, Johnson & Johnson Consumer Inc., Medtronic, Acandis GmbH, Terumo Corporation, Balt USA LLC, Stryker Corporation, and Guerbet LLC are among the leading companies operating in the embolotherapy market.

Based on disease indication, the embolotherapy market is segmented into cancer, peripheral vascular disease, neurological disease, urological and nephrological disorder, gastrointestinal disorder, and other. In 2021, the cancer segment accounted for the largest share of the market. Moreover, the same segment is anticipated to grow at the fastest rate during the forecast period. Embolization has become the accepted treatment modality in patients with many clinical scenarios. Embolization treats cancers such as neuroendocrine tumors, renal cell carcinoma, and hepatocellular carcinoma. The goal of embolization in cancer treatment is usually to cause ischemia within the tumor, which leads to tumor necrosis. This effect may be enhanced by adding a chemotherapeutic drug to the embolic substance which is referred chemoembolization. Another aim of embolization in cancer treatment is to remove a tumor that cannot be removed surgically because it is situated deep in the body. Thus, embolotherapy is rapidly becoming a preferred treatment for cancer as it cuts the tumor from the blood supply, starving it of nutrients. In addition, rising incidences of cancer worldwide coupled with the respective adoption of Transarterial chemoembolization (TACE) and Transcatheter Arterial Radioembolization (TARE) procedures is likely to spur the market growth during the forecast period.

Buy Report @ https://www.theinsightpartners.com/buy/TIPRE00006432/?utm_source=OpenPR&utm_medium=10381

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Ankit Mathur
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876

About US
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Food and Beverages, Consumers and Goods, Chemicals and Materials.

This release was published on openPR.